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Background: A wealth of nuclear receptor binding data has been generated by the application of chromatin
immunoprecipitation (ChIP) techniques. However, there have been relatively few attempts to apply these datasets
to human complex disease or traits.
Methods: We integrated multiple oestrogen receptor alpha (ESR1) ChIP datasets in the Genomic Hyperbrowser. We
analysed these datasets for overlap with DNase I hypersensitivity peaks, differentially expressed genes with estradiol
treatment and regions near single nucleotide polymorphisms associated with sex-related diseases and traits. We
used FIMO to scan ESR1 binding sites for classical ESR1 binding motifs drawn from the JASPAR database.
Results: We found that binding sites present in multiple datasets were enriched for classical ESR1 binding motifs,
DNase I hypersensitivity peaks and differentially expressed genes after estradiol treatment compared with those
present in only few datasets. There was significant enrichment of ESR1 binding present in multiple datasets near
genomic regions associated with breast cancer (7.45-fold, p = 0.001), height (2.45-fold, p = 0.002), multiple sclerosis
(5.97-fold, p < 0.0002) and prostate cancer (4.47-fold, p = 0.0008), and suggestive evidence of ESR1 enrichment for
regions associated with coronary artery disease, ovarian cancer, Parkinson’s disease, polycystic ovarian syndrome
and testicular cancer. Integration of multiple cell line ESR1 ChIP datasets also increases overlap with ESR1 ChIP-seq
peaks from primary cancer samples, further supporting this approach as helpful in identifying true positive ESR1
binding sites in cell line systems.
Conclusions: Our study suggests that integration of multiple ChIP datasets can highlight binding sites likely to
be of particular biological importance and can provide important insights into understanding human health and
disease. However, it also highlights the high number of likely false positive binding sites in ChIP datasets drawn
from cell lines and illustrates the importance of considering multiple independent experiments together.* Correspondence: adam.handel@gmail.com
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Many diseases are typified by an unequal prevalence in
females and males [1]. This gender disparity is particularly
marked for autoimmune diseases, especially multiple
sclerosis (MS) where the gender ratio is 2–3:1 [2,3].
Coronary artery disease (CAD) has a lower frequency
in premenopausal women and male gender is associated
with higher mortality [1,4]. Parkinson’s disease (PD) is
more frequent amongst males than females [5]. Clearly
certain diseases are either almost or completely gender-
specific, such as gynaecological, testicular and prostate
cancer.
Much molecular work has focussed upon potential
mechanisms underlying gender disparity observed in
many of the above diseases. In autoimmunity, oestrogen
has been shown to inhibit T-cell expansion and, in MS,
alters T-cell proliferation and cytokine secretion in
response to neutrally-derived antigens [6-9]. Oestrogen
also has been shown to promote neuronal survival in
neurodegenerative and neuroinflammatory conditions,
including PD and MS [10-12]. The cardioprotective effects
of oestrogen are well-described and are thought to be
mediated by vasodilatation and decreased atherosclerosis
[13]. Oestrogen receptor alpha (ESR1) is required for
the vasoprotective effects of oestrogen [14]. Oestrogen
replacement therapy has a well-described association
with gynaecological malignancy [15]. Differential ESR1
binding is associated with outcome following breast
cancer and altered ESR1 expression in ovarian cancer is
associated with prognosis [16,17]. A role for oestrogen
in testicular and prostate cancer has also been recog-
nised [18-21].
Chromatin immunoprecipitation with chip hybridisation
(ChIP-chip) or with massively parallel sequencing (ChIP-
seq) has generated a vast amount of data in multiple
different cell types regarding ESR1 binding across the
genome. Combining ESR1 ChIP-seq datasets have provided
insights into enhancer activity [22,23]. There is great
potential from combining transcription factor ChIP-seq
or epigenomics to provide insights into disease patho-
physiology [24]. Previous studies have revealed enrichment
for disease-associated variants with markers of open
chromatin and disease-relevant transcription factor bind-
ing sites [25-28].
We aimed to analyse whether ESR1 binding is enriched
in regions associated with diseases and traits that show
marked gender disparity and to what extent biologically
important information can be obtained by combining
ChIP-chip/-seq data obtained by different methodologies.
Our study differs from previous attempts to integrate
ESR1 ChIP studies by assessing the degree to which
useful information can be obtained regardless of specific
methodology used. Our hope is that our findings may
allow further functional work to focus on candidatevariants likely to be important in diseases or traits
showing sexual disparity. It is also likely that many
ESR1 ChIP peaks are false positives and we aimed to
assess whether overlap between different ChIP datasets
may enable identification of peaks that are more likely
to be true positive binding sites [29].
Methods
ChIP-chip/-seq data
We included 15 ESR1 ChIP-chip/-seq datasets where
cells had been stimulated with estradiol prior to ChIP
from Cistrome and Medline [30-42]. We also included
ESR1 ChIP-seq peaks common to all primary cancer cell
samples from breast cancer patients [16]. The character-
istics of these studies are shown in Additional file 1:
Table S1.
Motif analysis
De novo motif discovery was undertaken using MEME-
ChIP searching the central 200 bases within each bind-
ing interval for either one or no motif per site between
6 and 30 bases in length [43]. STAMP was used to analyse
motifs generated by MEME-ChIP for similarity between
different datasets using the settings “Metric = PCC,
Alignment = SWU, Gap-open = 1000, Gap-extend = 1000,-
nooverlapalign Multiple Alignment = IR, Tree = UPGMA,
Matching against: user-defined” [44]. The central 200
basepairs of each binding site and the region within 20
bases of SNPs either associated with disease or in linkage
disequilibrium with r2 ≤ 0.8 were scanned for JASPAR
2009 ESR1 binding motif (MA0112.2) occurrences with
p ≤ 0.0001 using FIMO [45].
ESR1 enrichment within disease/trait-associated genomic
regions and hierarchal clustering analysis
The Genomic HyperBrowser was used to determine over-
lap and hierarchical clustering between different datasets
[46,47]. Tracks comprising different genomic features
are annotated as segments, which are different stretches of
specific chromosomes, or points, which are basepair
locations on specific chromosomes. We defined disease-
associated genomic regions as those within 100 kb of
SNPs in the Genome Wide Association Study Catalogue
(downloaded on 30/03/2013) with a p-value ≤1×10-7 for
pre-defined conditions/traits with known gender disparity
(androgen levels, estradiol levels, breast cancer, coronary
heart disease, height, male baldness, menopause, menarche,
migraine, multiple sclerosis, ovarian cancer, Parkinson’s
disease, polycystic ovarian syndrome, prostate cancer,
sex hormone binding globulin levels and testicular cancer)
in a similar manner to a previous study [48,49]. Overlap
was determined using segment-segment analysis with
10,000 Monte-Carlo randomisations maintaining the
empiric distribution of segment and inter-segment lengths,
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based on the proximity of all ESR1 binding sites to the
nearest gene. ESR1 binding intervals were represented
as points (midpoints of ESR1 binding peaks) and a
point-segment analysis using 1,000 Monte-Carlo rando-
misations with points sampled according to the intensity
track, were used to compute p-values (disease/trait-
associated regions were represented as segments as
before). Hierarchical clustering analysis was performed
in the Genomic HyperBrowser by obtaining pairwise
overlap-enrichment values for each of the samples and
computing distance between samples as the inverse
of these values. DNase I hypersensitivity peaks were
obtained from UCSC Table Browser [50] and GRO-seq
data on differentially expressed genes with estradiol
treatment (q ≤ 0.001 for at least one timepoint) from
[51]. The midpoint of ESR1 binding sites were classi-
fied as falling within exons, introns, UTR, up-/down-/
up&down-stream (5 kb) or intergenic regions relative
to RefSeq genes.
Results
ESR1 binding sites in different datasets
The characteristics of each study are shown in Additional
file 1: Table S1. Overall, between the 15 datasets,
127,193 ESR1 binding sites were identified. 89,964
(70.7%) were unique to a single dataset, 19,833 (15.6%)
were common to at least 3 datasets, 8,390 (6.6%) to at
least 5 datasets, 2,880 (2.3%) to at least 8 datasets and
897 (0.7%) to at least 11 datasets. Even when restricting
analysis to only those studies conducted in MCF-7 cells
exposed to estradiol for 45 minutes, 69.1% of binding
sites were unique to a single dataset. Certain regions of
the genome are known to generate false positive ChIP-seq
peaks, however, only a minority of ESR1 binding sites are
located within these regions, and none which are common
to highly shared binding sites (Additional file 1: Table S2)
[52]. The genomic distribution of ESR1 binding sites
was similar regardless of the shared number of datasets
(Additional file 1: Table S3). In 12 datasets, the top motif
identified by MEME was highly similar to the consensus
ESR1 motif on JASPAR 2009 [53] (Additional file 2: FigureFigure 1 MEME-identified motifs within ESR1 binding sites in commo
TOMTOM similarity to known motifs (JASPAR (upper case) and uniprobe mS1). The motifs in those 12 showed significant similarity
with one another when analysed in STAMP, as did motifs
detected in the remaining three, although these were of
uncertain biological significance. In all datasets, DREME
identified motifs showing significant similarity to ESR1
motifs (Additional file 3: Figure S2). Motif analysis
conducted on intervals shared between datasets is shown
in Figure 1. In each case, the top motif identified showed
significant similarity to the consensus ESR1 motif. The
presence of a JASPAR 2009 consensus ESR1 motif (at
p ≤ 0.0001) was significantly correlated with the number
of shared datasets for each binding site from 13.7% of
binding sites unique to a single dataset to 46.3% of
those shared between all 15 datasets (r2 = 0.71, p = 0.0008,
Additional file 1: Table S4). We conducted MEME and
DREME analysis in those ESR1 ChIP-seq peaks shared
between at least 5 datasets that were found to lack a
classical ESR1 recognition motif. MEME was unable to
identify any ESR1-like motifs but did identify an SP1-like
motif (Additional file 4: Figure S3). The top DREME motif
was a FOXA1 binding motif and the second was a partial
ESR1/2 motif, suggesting that in some binding intervals
lacking the classical ESR1 recognition motif, ESR1
may interact with a degenerate motif. FOXA1 has been
described as a binding partner of ESR1 in previous
studies and is involved in chromatin interactions [54].
Interestingly MEME and DREME did not identify any
FOXA1-like motif in ChIP-seq peaks containing ESR1
classical motifs but did identify similar SP1-like motifs.
Hierarchical clustering analysis showed that the ESR1
ChIP datasets conducted in cells derived from uterine
tissue cluster together but there was no other obvious
clustering based on either the type of breast cancer
cells or the length of estradiol treatment used (Figure 2).
Only two studies explicitly detailed the use of more
than one biological replicates per treatment condition
(Carroll et al. [30] and Hurtado et al. [31]) and there
was a trend towards a lower proportion of ESR1 ChIP-seq
peaks being unique to a single dataset in these (r2 =
0.19, p = 0.054) and a higher proportion of highly
shared peaks, which reached significance in those
shared between 8 and 10 datasets (8 datasets: r2 = 0.27,n between datasets. E-values are shown for each motif along with
ouse (lower case) with E-value <10).
Figure 2 Hierarchical clustering of ESR1 binding sites between different datasets. (A) A dendrogram and heatmap of genomic binding
illustrating clustering between different datasets. (B) A heat map showing relative distances between pairs of datasets (red = 0.000 to dark
green = 0.036; units are the inverse of pairwise overlap between ChIP datasets). Study details show the first author, tissue type, cell type and
length of estradiol treatment.
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r2 = 0.21, p = 0.04).
ESR1 enrichment within disease/trait-associated regions
There was highly significant enrichment of ESR1 binding
sites within genomic regions associated with breast cancer,
height, MS and prostate cancer, which was consistent
over multiple datasets and increased in magnitude for
binding sites shared between multiple datasets (Additional
file 1: Table S5, Table 1). There was suggestive enrichmentfor CAD, ovarian cancer, Parkinson’s disease, polycystic
ovarian syndrome and testicular cancer, although these
were not consistent findings across all datasets. ESR1
binding site enrichment within disease/trait-associated
regions remained significant when controlling for the
position of genes. We also assessed disease/trait overlap
using the central 200 bases of each binding site to control
for differing size of binding sites and found very similar
results (Additional file 1: Table S6). 645 SNPs either
directly associated with diseases/traits or in strong linkage
Table 1 Enrichment of ESR1 binding sites within genomic regions associated with diseases or traits from GWAS
GWAS disease/trait All ESR1 ESR1 in ≥3 datasets ESR1 in ≥5 datasets ESR1 in ≥8 datasets ESR1 in ≥11 datasets
O/E p O/E p O/E p O/E p O/E p
Androgen levels 1.02 0.8857 0.75 0.8063 0.67 0.9093 1.60 0.4880 4.47 0.1062
Estradiol levels 1.67 0.8659 1.21 0.7437 1.06 0.8905 1.82 0.6311 0.00 1.0000
Breast cancer 2.09 0.0002 3.21 0.0004 3.92 0.0012 5.98 0.0038 7.45 0.0012
(0.002) (0.002) (0.002) (0.002) (0.002)
Coronary artery disease 1.43 0.0002 1.69 0.0068 1.74 0.0270 1.90 0.0704 0.49 0.4322
(0.002) (0.002) (0.005)
Height 1.55 0.0002 1.77 0.0002 1.87 0.0004 2.36 0.0012 2.45 0.0018
(0.002) (0.002) (0.002) (0.004) (0.004)
Male baldness 0.75 0.1652 0.42 0.1840 0.37 0.3384 0.41 0.7137 1.16 0.5043
Menopause 1.05 0.8431 0.89 0.7393 0.67 0.4668 0.59 0.5813 0.64 0.9471
Menarche 1.11 0.4504 1.20 0.5341 1.30 0.4410 1.60 0.2680 1.07 0.9173
Migraine 1.29 0.2036 1.55 0.2554 2.42 0.0618 1.32 0.6031 0.00 1.0000
Multiple sclerosis 2.98 0.0002 2.98 0.0002 3.40 0.0002 4.22 0.0008 5.97 0.0002
(0.002) (0.002) (0.002) (0.002) (0.047)
Ovarian cancer 1.79 0.0134 1.93 0.2676 2.64 0.1596 3.61 0.1564 0.00 1.0000
(0.002)
Parkinson’s disease 1.54 0.0228 1.65 0.2158 1.62 0.3910 1.17 0.9067 1.35 0.9077
(0.002)
Polycystic ovarian syndrome 2.42 0.0002 3.60 0.0038 2.20 0.3386 1.79 0.6467 3.21 0.3286
(0.002) (0.022)
Prostate cancer 1.82 0.0002 2.40 0.0002 2.62 0.0006 2.76 0.0168 4.47 0.0008
(0.002) (0.002) (0.002) (0.002) (0.002)
Sex hormone binding globulin levels 1.09 0.8553 0.70 0.4008 0.46 0.2856 0.29 0.3958 0.00 1.0000
Testicular cancer 1.52 0.0056 1.36 0.3218 0.57 0.7883 0.92 0.7523 2.59 0.1498
(0.002)
Enrichment is shown by differing numbers of shared datasets. Significant enrichment is highlighted in bold and the p-value corrected for genomic location of
genes is shown in parenthesis after nominally significant enrichments. O/E = observed/expected ratio.
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sites but only 12 of these directly disrupted a classical
ESR1 recognition motif (Additional file 1: Table S7).
DNase I hypersensitivity peaks, gene expression and
ESR1 binding
ESR1 binding sites were significantly enriched for DNaseI
hypersensitivity peaks drawn from multiple cell types
(Ecc-1, Ishikawa, MDF-7, T47D, LNCaP, HUVEC, glioma
and Th1 CD4+, Additional file 1: Table S8). Interestingly,
for all apart from Th1 CD4+ cells (r2 = 0.05, p = 0.41),
HUVEC (r2 = 0.002, p = 0.86) and glioblastoma (r2 = 0.05,
p = 0.41), there was a significant correlation between
the number of shared datasets at each ESR1 binding site
and the enrichment for DNase I hypersensitivity peaks
(Ecc-1 r2 = 0.75, p < 0.0001; Ishikawa r2 = 0.70, p < 0.0001;
MCF7 r2 = 0.67, p = 0.0002; T47D plus estradiol r2 = 0.97,
p < 0.0001; T47D r2 = 0.82, p < 0.0001; and LNCaP r2 = 0.61,
p = 0.0006; Figure 3). This relationship was maintainedwhen ESR1 binding sites were trimmed to the central
200 basepairs to control for differing binding site lengths.
ESR1 binding in regions associated with MS were highly
enriched for Th1 CD4+ DNase I hypersensitivity peaks
(7.41-fold, p < 0.0002) and those in regions associated
with prostate cancer for LNCaP DNase I hypersensitivity
peaks (9.39-fold, p < 0.0002).
There was significant enrichment of ESR1 binding
sites with 5 kb of genes differentially expressed following
estradiol treatment (Additional file 1: Table S8) [51]. The
degree of enrichment was highly correlated with the
number of shared datasets for each ESR1 binding site
(r2 = 0.89, p < 0.0001), which again was unaffected by
restricting analysis to only the central 200 basepairs of
each binding interval (r2 = 0.94, p < 0.0001).
Biological significance of motif/DNase I hypersensitivity
We divided ESR1 binding sites into those with and with-
out ESR1 classical motifs. There was some evidence that
Figure 3 Enrichment of ESR1 binding sites within DNase I hypersensitivity peaks. Different cell types are shown as different series
where E2 = estradiol-treated.
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located near disease/trait-associated regions than those
without in (breast cancer, coronary artery disease, height,
Parkinson’s disease and prostate cancer) but this was not
true for all diseases/traits (Additional file 1: Table S9).
Motif-containing binding sites were consistently more
enriched for DNase I hypersensitivity peaks in all cell
types and within 5 kb of genes expressed differently with
estradiol treatment than those without motifs.
We also separated ESR1 binding sites into those over-
lapping and not overlapping DNase I hypersensitivity peaks.
Disease/trait-associated regions were highly enriched
for DNase I hypersensitivity peaks (Figure 4; Additional
file 1: Table S9). Motif analysis on ESR1 binding sites
overlapping and not overlapping DNase I hypersensitivity
peaks common to at least 5 datasets showed ESR1
recognition motifs as the top motif in both cases.
Similarly, in both cases motifs similar to FOXA1 were
identified.
Primary cancer ESR1 ChIP-seq
It is possible that the ESR1 ChIP overlap findings are
biased by being conducted in cell lines. We analysed
ESR1 ChIP-seq data drawn from primary breast cancer
samples in relation to GWAS disease/trait regions,
DNase I hypersensitivity peaks and estradiol-induced
gene expression (Additional file 1: Table S10) [16]. There
was significant enrichment of ESR1 binding in GWAS
regions associated with androgen levels (11.76-fold,
p = 0.02) and breast cancer (11.76-fold, p = 0.0008) with
trends for several other conditions/traits. There was highlysignificant enrichment of ESR1 binding within DNase I
hypersensitivity peaks from all cell types studied and near
genes differentially expressed with estradiol treatment.
There was a strong correlation between ESR1 ChIP-seq
peaks in primary cancer samples and the number of
shared datasets for each ESR1 binding site in cell lines
(r2 = 0.74, p < 0.0001), which was preserved when restrict-
ing analysis to only the central 200 basepairs of each
ESR1 binding site (r2 = 0.73, p < 0.0001).
Discussion
There is huge variation between individual ESR1 ChIP
experiments with most binding sites unique to a single
experiment. This may stem from the frequent use of
immortalised cell lines, which are known to accrue
mutations on prolonged culture and thus may generate
a large number of false positive binding sites [55,56].
ESR1 binding sites shared between multiple experiments
are likely to be more important to regulatory activity
given the higher enrichment of DNase I hypersensitivity
peaks, differentially expressed genes and ESR1 binding
motifs at highly shared sites compared with sites shared
only between few experiments. This is supported by in-
creased enrichment of ESR1 binding sites near regions as-
sociated with diseases/traits when those binding sites
contain motifs or DNase I hypersensitivity peaks. This
suggests that integrating multiple different published
ChIP datasets is important in mapping the most im-
portant binding sites for transcription factors and can
provide valuable biological insights even if the precise
methodologies used in each experiment differ [22]. Our
Figure 4 Enrichment of ESR1 binding sites overlapping and not overlapping DNase I hypersensitivity peaks within disease/trait-associated
regions. ESR1 binding sites are divided into those overlapping and not overlapping DNase I hypersensitivity peaks in the MCF7 breast cancer
cell line.
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datasets, especially in cell lines, is important to distinguish
true positive from false positive ChIP peaks. This is
supported by far higher overlap of ESR1 ChIP-seq peaks
in primary cancer cells with cell line ChIP peaks found
in multiple datasets. Our results also emphasise the im-
portance of analysing biological replicates. However,
one key limitation of ChIP-seq from primary cell lines
is that, due to the more differentiated nature of primary
cells, nuclear factor binding is less likely to be informative
of overlap with susceptibility regions in diseases not
primarily affecting that tissue type. Further work will
be needed to reveal whether similar relationships between
biological importance and preservation of ChIP peaks
in multiple datasets exists for other nuclear receptors and
transcription factors. This also underlines the importance
of uploading raw data on all ChIP experiments so that
datasets can be directly compared by calling peaks in the
same manner.
Interestingly, ESR1 ChIP peaks identified in breast or
uterine cell lines also show significant enrichment for
DNase I hypersensitivity peaks from other cell lines,
which suggests that functional annotation of the genome
may be able to cast some light even on biological pathwaysin cell lines far removed from the ChIP-seq material. This
makes the ENCODE approach a very powerful one, since
functional genomics data could potentially be used to
generate powerful hypotheses about biological systems
removed from the particular one used in an individual
experiment [57].
We found that ESR1 binding sites were strongly enriched
near regions associated with susceptibility to breast
cancer, height, MS and prostate cancer, suggesting
that ESR1 may contribute to the functional genomics
of these diseases. We have shown that susceptibility
SNPs frequently fall beneath ESR1 ChIP peaks and
thus suggest a possible functional basis for several GWAS
susceptibility SNPs. Some of these were supported by
ESR1 ChIP-seq peaks derived from primary cancer
samples but this is likely limited by the small number
of binding sites in common between samples and the
relatively differentiated nature of the chromatin archi-
tecture compared with cell lines. Further work should
concentrate on integrating expression data with known
ESR1 ChIP-seq peaks in order to dissect out the precise
details of this interaction between ESR1 binding and
disease susceptibility. Focussing on the variants highlighted
in our analysis for further functional studies may provide
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ESR1 binding. ESR1 is an attractive candidate, the binding
of which may underlie several diseases showing marked
gender disparity. This may ultimately permit the iden-
tification of novel biochemical pathways that provide
new therapeutic targets [58].Conclusions
We have shown that integration of ChIP datasets drawn
from multiple different cell lines is a powerful technique
to screen out false positive nuclear factor binding
sites. Moreover, ESR1 binding sites present in multiple
experiments were enriched for ESR1 ChIP-seq peaks
from primary cancer samples, DNase I hypersensitivity
regions, genes differentially expressed after exposure
to estradiol, and regions associated with diseases and
traits characterised by sexual disparity. Future work
should attempt to use primary cells whenever possible
and should focus on potential functional variants that
may be linked with human phenotypes identified in
this study.
Additional files
Additional file 1: We have included the following additional files.
Table S1. Characteristics of included studies; Table S2. ESR1 binding sites
overlapping with blacklisted regions; Table S3. Genomic location of ESR1
binding sites relative to the number of shared datasets; Table S4.
Frequency of ESR1 binding sites possessing at least one JASPAR ESR1 motif
(MA0112.2); Table S5. ESR1 enrichment within genomic regions associated
with diseases/traits (O/E = observed/expected); Table S6. ESR1 enrichment
within genomic regions associated with diseases/traits for central 200 bps of
each interval (O/E = observed/expected); Table S7. GWAS SNPs or those in
LD (r^2≥ 0.8) within ESR1 binding sites; Table S8. ESR1 enrichment within
DNase I hypersensitivity peaks and estradiol differentially expressed genes
(n.d. = not done); Table S9. ESR1 with and without motifs or DNase I
hypersensitivity peaks enrichment within genomic regions associated with
diseases/traits for central 200 bps of each interval (O/E = observed/expected;
DHS = DNase I hypersensitivity peaks); and Table S10. Overlap of ESR1
ChIP-seq binding sites from primary cancer samples (O/E = observed/
expected).
Additional file 2: Figure S1. MEME-identified motifs within ESR1
binding sites for individual datasets. E-values are shown for each motif
along with TOMTOM similarity to known motifs (JASPAR (upper case) and
uniprobe mouse (lower case) with E-value <10). Study details show the
first author, tissue type, cell type and length of estradiol treatment.
Additional file 3: Figure S2. ESR1-like DREME-identified motifs within
ESR1 binding sites for individual datasets. E-values are shown for each
motif along with TOMTOM similarity to known motifs (JASPAR (upper
case) and uniprobe mouse (lower case) with E-value <10). The motif
shown is the top motif by E-value for all except Carroll et al. (second top)
and Need et al. (third top). Study details show the first author, tissue type,
cell type and length of estradiol treatment.
Additional file 4: Figure S3. MEME- and DREME- identified motifs within
ESR1 binding sites without classical ESR1 recognition motifs. E-values are
shown for each motif along with TOMTOM similarity to known motifs
(JASPAR (upper case) and uniprobe mouse (lower case) with E-value <10).
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